Shares of BSE rose by 2 percent following the exchange's announcement that it will explore MSCI-linked derivatives in India. Additionally, BSE's subsidiary introduced new growth factor indices to broaden its market offerings.

Shares of BSE rose 2 per cent in early trade following the exchange's announcement that it would explore MSCI-linked derivatives in India. The move is aimed at boosting liquidity and trading activity in the domestic market.

As of 10:53 am on the National Stock Exchange (NSE), BSE shares recorded a traded volume of 19.88 lakh and a traded value of ₹672.03 crore. The company’s total market capitalisation stood at ₹1.37 lakh crore, with an adjusted price-to-earnings (PE) ratio of 48.45. By 10:58 am, the stock traded at ₹3,378.70, after earlier rising to ₹3,412 in the pre-open session.

Under the newly established agreement with MSCI for a number of its indexes, BSE will explore the launch of futures and options contracts in India linked to these indexes. The implementation remains subject to necessary regulatory approvals. BSE stated that this strategic step anchors its role in further developing the Indian capital market.

In a related development, BSE’s arm, BSE Index Services Pvt. Ltd., announced the launch of Growth Factor Indices. This suite comprises three indices: the BSE 500 Growth 50 Index, the BSE MidCap 150 Growth 30 Index, and the BSE LargeCap 100 Growth 30 Index.

Meanwhile, regulatory focus remains active in the market infrastructure space. SEBI Chairman Tuhin Kanta Pandey previously stated that the regulator would take strict and immediate action against any attempt to manipulate the Closing Auction Session (CAS). BSE’s Closing Auction Session is a 20-minute auction mechanism introduced on August 3, 2026, running from 3:15 pm to 3:35 pm for futures and options eligible stocks. It replaces the final continuous trading window to pool and match orders at a single equilibrium closing price.

"The decision by BSE to explore MSCI-linked derivatives and introduce new growth factor indices highlights ongoing efforts to deepen product offerings and enhance trading liquidity in the Indian capital market. For market participants and exchanges, expanding into global index-linked derivatives creates avenues for increased participation, subject to regulatory clearances. Strategic product diversification remains a key driver for market infrastructure institutions looking to strengthen their long-term position." — Dr. Shishir Gupta, Founder & CEO, StartupLanes

Recent StartupLanes Articles

Browse through our 30 latest publications on venture capital, startups, and angel investing.

Kalpataru Projects International Secures New Orders Worth ₹2,349 Crore Oct 22, 2026
MCX Copper Futures Decline From Recent Highs as Market Approaches Key Support Levels Oct 22, 2026
OpenAI Acquires Orchestra Bio to Expand Life Sciences and Drug Development Capabilities Oct 22, 2026
Dr. Reddy’s Laboratories Receives DCGI Approval for Toripalimab in India Oct 22, 2026
Anthropic's Confidential IPO Filing Reveals $80.7 Billion H1 Loss and Heavy Computing Costs Oct 22, 2026
Jio Platforms Launches ₹30,213 Crore IPO: Key Details, Valuations, and Brokerage Views Oct 22, 2026
State Bank of India Reports Suspected Customer Data Exposure on Dark Web Oct 22, 2026
US Secretary of State Marco Rubio Terms Envoy Meeting with Ukrainian President Positive Oct 22, 2026
Rupee Strengthens 29 Paise Against US Dollar in Early Trade, Supported by RBI and Jio IPO Inflows Oct 22, 2026
Brent Crude Stays Above $110 Amid West Asia Supply Concerns and Inventory Data Oct 22, 2026
Indian Market Updates: Corporate Earnings, Strategic Agreements, and Expansion Plans Across Sectors Oct 22, 2026
Corporate Updates: Infosys Expands Truist Collaboration, Cemindia Raises ₹1,400 Crore via QIP, and Multiple Firms Report Contracts and Acquisitions Oct 22, 2026
Centre to Review National Mineral Policy 2019 to Focus on Critical Minerals and Deep-Sea Resources Oct 22, 2026
Qualcomm Announces Global Job Cuts Following Annual Performance Reviews Oct 22, 2026
AstraZeneca Pharma Relocates Registered Office from Karnataka to Maharashtra Oct 22, 2026